AGFG1 and Alzheimer disease: Treating Dp16 mice with RAB5-specific antisense oligonucleotides normalized endosomal RAB activity and reversed AD-related phenotypes, including tau hyperphosphorylation and neurotrophin signaling deficits, supporting a direct role for RAB5 dysfunction in AD pathogenesis [7].